Microfluidic, marker-free isolation of circulating tumor cells from blood samples

作者：Karabacak, Nezihi Murat; Spuhler, Philipp S.; Fachin, Fabio; Lim, Eugene J.; Pai, Vincent; Ozkumur, Emre; Martel, Joseph M.; Kojic, Nikola; Smith, Kyle; Chen, Pin-i; Yang, Jennifer; Hwang, Henry; Morgan, Bailey; Trautwein, Julie; Barber, Thomas A.; Stott, Shannon L.; Maheswaran, Shyamala; Kapur, Ravi; Haber, Daniel A.; Toner, Mehmet^*

来源：Nature Protocols, 2014, 9(3): 694-710.

DOI：10.1038/nprot.2014.044

• BREAST-CANCER PATIENTS
• DETERMINISTIC LATERAL DISPLACEMENT
• PERIPHERAL-BLOOD
• MONOCLONAL-ANTIBODIES
• IMMUNOMAGNETIC ENRICHMENT
• PROSTATE-CANCER
• SEPARATION
• PROGRESSION
• CARCINOMA
• ANTIGEN

The ability to isolate and analyze rare circulating tumor cells (CTCs) has the potential to further our understanding of cancer metastasis and enhance the care of cancer patients. In this protocol, we describe the procedure for isolating rare CTCs from blood samples by using tumor antigen-independent microfluidic CTC-iChip technology. The CTC-iChip uses deterministic lateral displacement, inertial focusing and magnetophoresis to sort up to 10(7) cells/s. By using two-stage magnetophoresis and depletion antibodies against leukocytes, we achieve 3.8-log depletion of white blood cells and a 97% yield of rare cells with a sample processing rate of 8 ml of whole blood/h. The CTC-iChip is compatible with standard cytopathological and RNA-based characterization methods. This protocol describes device production, assembly, blood sample preparation, system setup and the CTC isolation process. Sorting 8 ml of blood sample requires 2 h including setup time, and chip production requires 2-5 d.

• 出版日期2014-3